Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low rates of recurrence after successful treatment of multidrug-resistant tuberculosis in Tomsk, Russia.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2015
Same author

Note: ε(T) dependence behavior in GaP diodes at high temperatures.

The Review of scientific instruments·2012
Same author

Relationship between CYP2E1 polymorphism and increase of ALT activity during therapy of patients with pulmonary tuberculosis.

Bulletin of experimental biology and medicine·2012
Same author

[Efficacy and tolerance of rezonizate in complex with fluoroquinolones or mycobutin on a model of experimental murine tuberculosis].

Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic]·2012
Same author

Note: Determination of temperature dependence of GaP bandgap energy from diode temperature response characteristics.

The Review of scientific instruments·2011
Same author

[Interferon alpha-2b in the complex therapy of patients with pulmonary tuberculosis concurrent with bronchoobstructive syndrome].

Tuberkulez i bolezni legkikh·2010

Related Experiment Video

Updated: Jun 22, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

[Rifapex, a new antituberculosis agent].

G B Sokolova, V A Krasnov, T A Reĭkhrud

    Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic]
    |June 9, 2009
    PubMed
    Summary

    Rifapentin (Rifapex) effectively treats newly diagnosed, drug-susceptible tuberculosis. It demonstrated efficacy during acute phases, treatment completion, and pre-surgery in 90 patients.

    Area of Science:

    • Pulmonology
    • Infectious Diseases
    • Pharmacology

    Background:

    • Tuberculosis (TB) remains a significant global health challenge.
    • Drug-susceptible TB requires effective and safe therapeutic regimens.
    • Rifapentin is a long-acting rifamycin with potential in TB treatment.

    Purpose of the Study:

    • To evaluate the clinico-roentgenologic and bacteriologic efficacy of rifapentin (Rifapex).
    • To assess the safety profile of rifapentin in combination therapy.
    • To investigate its utility in different phases of tuberculosis management.

    Main Methods:

    • A study involving 90 patients with newly diagnosed drug-susceptible tuberculosis.
    • Complex therapy incorporating rifapentin (Rifapex).
    • Assessment of clinical, radiological, and bacteriological outcomes.

    Related Experiment Videos

    Last Updated: Jun 22, 2026

    Assay Development for High-Throughput Drug Screening Against Mycobacteria
    07:50

    Assay Development for High-Throughput Drug Screening Against Mycobacteria

    Published on: October 25, 2024

    Main Results:

    • Rifapentin (Rifapex) demonstrated significant efficacy in treating patients.
    • Effectiveness was observed during the acute phase of the disease.
    • Positive outcomes were noted for treatment completion and the preoperative period.

    Conclusions:

    • Rifapentin (Rifapex) is an effective component in the complex therapy of drug-susceptible tuberculosis.
    • Its safety and efficacy support its use in acute disease, treatment completion, and pre-surgical management.
    • Rifapentin offers a valuable therapeutic option for newly diagnosed TB patients.